193 related articles for article (PubMed ID: 3049800)
1. Idiotypic vaccination as a treatment for a B cell lymphoma.
George AJ; Folkard SG; Hamblin TJ; Stevenson FK
J Immunol; 1988 Sep; 141(6):2168-74. PubMed ID: 3049800
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of idiotypic vaccination in mice bearing B-cell lymphoma.
Khan NA
In Vivo; 1989; 3(2):117-9. PubMed ID: 2519837
[TBL] [Abstract][Full Text] [Related]
3. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.
George AJ; Tutt AL; Stevenson FK
J Immunol; 1987 Jan; 138(2):628-34. PubMed ID: 3491853
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibition of a B cell leukemia: evidence implicating an anti-idiotype immune response for protective tumor immunity.
Ciavarra RP; Vitetta ES; Forman J
J Immunol; 1986 Aug; 137(4):1371-5. PubMed ID: 2426362
[TBL] [Abstract][Full Text] [Related]
5. Idiotype vaccination leads to the emergence of a stable surface Ig-negative variant of the mouse lymphoma BCL1, with different growth characteristics.
George AJ; Spellerberg MB; Stevenson FK
J Immunol; 1988 Mar; 140(5):1695-701. PubMed ID: 3162250
[TBL] [Abstract][Full Text] [Related]
6. Molecules recognized by anti-idiotypic monoclonal antibodies to the B cell lymphoma, BCL1.
Tamura GS; McGrath MS; Weissman IL
J Mol Cell Immunol; 1987; 3(4):243-53. PubMed ID: 3509925
[TBL] [Abstract][Full Text] [Related]
7. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
Campbell MJ; Esserman L; Byars NE; Allison AC; Levy R
J Immunol; 1990 Aug; 145(3):1029-36. PubMed ID: 2373859
[TBL] [Abstract][Full Text] [Related]
8. Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells.
King CA; Wills MR; Hamblin TJ; Stevenson FK
Cell Immunol; 1993 Apr; 147(2):411-24. PubMed ID: 8095858
[TBL] [Abstract][Full Text] [Related]
9. Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection.
Benvenuti F; Burrone OR; Efremov DG
Gene Ther; 2000 Apr; 7(7):605-11. PubMed ID: 10819576
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the spontaneous murine B cell leukemia (BCL1). III. Evidence for monoclonality by using an anti-idiotype antibody.
Vitetta ES; Yuan D; Krolick K; Isakson P; Knapp M; Slavin S; Strober S
J Immunol; 1979 May; 122(5):1649-54. PubMed ID: 109513
[TBL] [Abstract][Full Text] [Related]
11. Novel mechanisms of specific suppression of anti-hapten antibody response mediated by monoclonal anti-carrier antibody.
Sumida T; Taniguchi M
J Immunol; 1985 Jun; 134(6):3675-81. PubMed ID: 3157746
[TBL] [Abstract][Full Text] [Related]
12. Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2.
Wang X; Ko EC; Peng L; Gillies SD; Ferrone S
Cancer Res; 2005 Aug; 65(15):6976-83. PubMed ID: 16061683
[TBL] [Abstract][Full Text] [Related]
13. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.
Campbell MJ; Carroll W; Kon S; Thielemans K; Rothbard JB; Levy S; Levy R
J Immunol; 1987 Oct; 139(8):2825-33. PubMed ID: 3498771
[TBL] [Abstract][Full Text] [Related]
14. The targeting of CD4+ T lymphocytes to a B cell lymphoma. A comparison of anti-CD3-anti-idiotype antibody conjugates and antigen-anti-idiotype antibody conjugates.
Gravelle M; Ochi A
J Immunol; 1989 Jun; 142(11):4079-84. PubMed ID: 2523940
[TBL] [Abstract][Full Text] [Related]
15. B-1a cell origin of the murine B lymphoma line BCL1 characterized by surface markers and bacterial reactivity of its surface IgM.
Koganei S; Ito M; Yamamoto K; Matsumoto N
Immunol Lett; 2005 May; 98(2):232-44. PubMed ID: 15860223
[TBL] [Abstract][Full Text] [Related]
16. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
Kwak LW; Campbell M; Levy R
Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
Kwak LW; Young HA; Pennington RW; Weeks SD
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
[TBL] [Abstract][Full Text] [Related]
18. Assessment of a functional role of auto-anti-idiotypes in idiotype dominance.
Ismaili J; Brait M; Leo O; Urbain J
Eur J Immunol; 1995 Mar; 25(3):830-7. PubMed ID: 7705415
[TBL] [Abstract][Full Text] [Related]
19. Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma.
Weiner GJ; Kaminski MS
J Immunol; 1990 Mar; 144(6):2436-45. PubMed ID: 1690244
[TBL] [Abstract][Full Text] [Related]
20. Recognition of a B cell lymphoma by anti-idiotypic T cells.
Wilson A; George AJ; King CA; Stevenson FK
J Immunol; 1990 Dec; 145(11):3937-43. PubMed ID: 2246520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
